NEW: Our Medical Director Dr Amit Aggarwal's comment on NHS-industry partnerships and the safeguards in place to manage conflicts of interest.
Companies may also benefit from partnerships, but the priority has to be to put the NHS & patients first.
www.abpi.org.uk/media/blogs/...
Our colleague Brian Duggan spoke at the APPG for Black Health event on increasing diversity in clinical trials @paulettehamiltonmp.bsky.social
Lack of diversity in clinical trials is a huge issue that has real consequences for health.
Read his reflections: abpi.org.uk/media/blogs/...
This @careersweek.bsky.social we're showcasing the diverse range of roles within the pharmaceutical industry.
If you’re exploring your next step or curious about what a career in the industry can look like visit our job cases studies: www.abpi.org.uk/careers/job-...
www.youtube.com/watch?v=uaoE...
Equity in rare diseases means equal access to diagnosis, treatment, health and social care, and the opportunity to fully participate in society.
Read the @geneticallianceuk.bsky.social report on this: geneticalliance.org.uk/wp-content/u... #RareDiseaseDay #RareEquity
For #RareDiseaseDay we’re sharing Alan’s amazing journey with ataxia - he founded Ataxia and Me to raise awareness and connect people around the world. 🌍
Thanks to @geneticallianceuk.bsky.social for championing every voice in the rare disease community. 💪
abpi.org.uk/media/blogs/...
For Emily Reuben, CEO, Duchenne UK, equity in rare disease means removing barriers to children getting new treatments. They call for a children’s health technology assessment pathway with achievable evidence standards. #RareDiseaseDay @geneticallianceuk.bsky.social
www.abpi.org.uk/rare-disease...
In a guest blog for #RareDiseaseDay, Laurence Woollard
reflects on what haemophilia gene therapy teaches us about equity, access & adoption of advanced therapies in the NHS.
@geneticallianceuk.bsky.social @cgtcatapult.bsky.social
Read it here: www.abpi.org.uk/media/blogs/...
🚨New: Blog from our colleague Dan O'Connor for #RareDiseaseDay: Prevention can be the most powerful treatment of all.
A timely read highlighting why equity & prevention are vital. @geneticallianceuk.bsky.social
🔗 Read more: www.abpi.org.uk/media/blogs/...
#RareDiseaseDay2026 #rarequity
Our colleague Dan O'Connor attended the packed @geneticallianceuk.bsky.social Rare Disease Day event yesterday. 🧑🤝🧑
Great to see so many people calling for equity for rare diseases.
Download the @geneticallianceuk.bsky.social's advocacy pack 👉http://bit.ly/4rp81yB
#rarequity #RareDiseaseDay
✨Meet Anna! She lives with rare bone condition hypophosphatasia (HPP), but nothing stops her.
On #RareDiseaseDay, we celebrate Anna and every person with a rare disease. @geneticallianceuk.bsky.social
Read her story: www.abpi.org.uk/media/blogs/...
This year’s @geneticallianceuk.bsky.social #RareDiseaseDay focuses on equity and why it matters more than ever.
Chris Walden, CEO of @cancer52org.bsky.social, reflects on what equity means in practice.
Read the full Q&A on the ABPI rare disease hub:
👉https://www.abpi.org.uk/rare-diseases/
The theme of this year's #RareDiseaseDay is equity.
In our Q&A, Rick Thompson, CEO of Beacon: for rare diseases reflects on what equity means for him and his organisation.
Read more at the ABPI's rare disease hub www.abpi.org.uk/rare-diseases/ @rarediseaseday.bsky.social
Many medicines entering clinical trials fail because pre-clinical testing does not accurately predict effects in humans.
A key reason? A gap between some 'pre-clinical models' and industry needs.
A new ABPI/@nc3rs.bsky.social review sets out how to close this gap. abpi.org.uk/publications...
We are delighted to publish a report with @abpi.bsky.social that examines the UK landscape in human relevant in vitro models. It will help inform wider policy, funding and infrastructure requirements to accelerate translation and deliver benefits for pharmaceutical R&D. nc3rs.org.uk/news/landsca...
🚨The UK has a major opportunity to accelerate the development of new medicines 🧬
A new report from ABPI & @nc3rs.bsky.social shows how to help pre-clinical models turn potential medicines into real-world treatments.
🧷 www.abpi.org.uk/media/news/2...
Thinking about a career in the pharmaceutical industry?
It's #NationalApprenticeshipWeek & we are sharing the different routes into the industry, including apprenticeships, & the opportunities they open up.
Take a look: www.abpi.org.uk/careers/job-...
www.youtube.com/watch?v=fxXR...
#NAW2026
Despite continued advances in cancer research, UK patients can access fewer cancer medicines through the NHS than patients in comparable European countries.
Find out more about improving access to cancer medicines:
www.abpi.org.uk/publications...
What drives company decisions on new medicine launches and UK investment?
The findings of ABPI's 2025 Medicines Impact and Investment Survey track how UK policy conditions influence companies' investment and prioritisation decisions for medicines launches.
www.abpi.org.uk/media/blogs/...
At the moment, NHS patients with blood cancer can only access half of the approved medicines for their condition.
Reviewing how these medicines are valued is a first step to giving UK patients the treatments that could save or prolong their lives.
Learn more: www.ourcommongoal.org.uk/blood-cancer/
New breast cancer treatments can extend patients’ lives, yet some remain unavailable in parts of the UK.
Rethinking the way such medicines are valued and approved is a crucial first step in increasing access to life-extending care for more UK patients.
Find out more: www.ourcommongoal.org.uk
It's time to emphasise the economics in health economics. Victoria Jordan discusses the health economics of the UK-US Economic Prosperity Deal and plans increase NICE's baseline threshold use, the first change since its introduction in the early 2000s. abpi.uksouth01.umbraco.io/media/blogs/...
Alzheimer’s devastates the lives of patients and their families, costing billions in care.
New treatments that can slow the disease’s progression in its early stages have recently been licensed in the UK - yet NHS patients are still being denied access.
Find out more: www.ourcommongoal.org.uk
#ABSWawards
As we prepare for the ABSW Awards 2026, we want to thank the partners whose continued support helps us celebrate excellence in science journalism...
@abpi.bsky.social
Dr Katharine Giles Fund
@royalsociety.org
AlphaGalileo
Want to be an ABSW Awards partner?
Find how👉 zurl.co/gPGgo
Publication of 'A Common Understanding 2025' marked an important milestone for collaborative working in Scotland earlier this year.
It shows how partnership across industry, academia & the NHS can improve patient care & drive innovation.
www.gov.scot/publications...
We’re proud to share our guidance on creating successful NHS-industry partnerships in Northern Ireland’s health & social care system.
Developed with @niconfederation.bsky.social, it’s designed to accelerate innovation and improve patient outcomes. www.abpi.org.uk/publications...
Earlier this year we launched joint guidance with @welshnhsconfed.bsky.social to help the NHS and industry work together more confidently, transparently & effectively.
📘 Download here to create successful partnerships for your organisation www.nhsconfed.org/publications...
#PartnershipWorking
NHS–industry partnership guidance is now in place across all 4 UK nations.
Developed with @nhsconfed.org, @welshnhsconfed.bsky.social, @niconfederation.bsky.social, and the Scottish Government, these frameworks support better outcomes for patients ⬇️
Find out more at www.abpi.org.uk/partnerships/
The payment rates for older branded medicines remain unchanged in 2026, with companies continuing to pay between 10% and 35% on their sales of each older medicine to the NHS, depending on the levels of price discount already offered to the NHS.
The VPAG payment rate for newer medicines will be 14.5% in 2026. With the addition of the 1% investment programme, the total rebate for newer medicines in 2026 will be 15.5% of revenues.
www.abpi.org.uk/media/news/2...
There’s been a drop in ppl participating in interventional industry clinical trials 📉
There are many potential reasons for this - lots of action underway to fix it 🔧
We're proposing further measures in our latest report.
abpi.org.uk/publications... @nihr.bsky.social
